Can I Get Medical Cannabis on the NHS?

The NHS will routinely fund only three specific, pharmaceutical-grade cannabinoid medications that have received formal marketing authorization (licenses) from the Medicines and Healthcare products Regulatory Agency (MHRA):

1. Epidyolex (cannabidiol): A highly purified (>98% pure), plant-derived CBD oral solution manufactured by GW Pharmaceuticals/Jazz Pharmaceuticals. It contains negligible THC (<0.1%). It is licensed strictly as an add-on therapy alongside clobazam for severe childhood-onset epilepsies — specifically Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex (TSC). Prescriptions must be initiated by tertiary NHS paediatric neurologists.

2. Sativex (nabiximols): An oral mucosal spray containing a precise 1:1 ratio of THC (2.7mg per spray) and CBD (2.5mg per spray) extracted from cloned cannabis plants. Sativex is licensed exclusively for treating moderate-to-severe spasticity in adult Multiple Sclerosis (MS) patients who have failed to respond to first-line antispasmodics like baclofen or tizanidine. Even for MS, local Integrated Care Boards (ICBs) vary widely in their willingness to approve funding.

3. Nabilone (Cesamet): A synthetic cannabinoid analogue that chemically mimics delta-9-THC. It is licensed strictly for managing refractory chemotherapy-induced nausea and vomiting (CINV) in oncology patients who have not responded to standard antiemetics such as ondansetron or dexamethasone. It is almost exclusively dispensed in hospital oncology wards.

Crucially, no NHS trust or ICB routinely funds raw cannabis flos (flower for dry herb vaporization) or full-spectrum botanical extracts, despite these making up more than 90% of prescriptions in the private medical cannabis sector.

When an NHS specialist doctor believes an unlicensed cannabis product is necessary for a patient outside standard NICE criteria, they must submit an Individual Funding Request (IFR) to the patient's local Integrated Care Board (ICB).

An IFR requires the clinical team to prove 'exceptionality' — demonstrating not only that the patient has a severe, treatment-resistant condition, but that their clinical circumstances are significantly different from other patients with the same diagnosis, and that they will derive unique clinical benefit that justifies the public cost.

In practice, over 95% of cannabis-related IFR applications are rejected at the panel review stage. Commissioning panels frequently cite lack of cost-effectiveness, absence of phase-3 clinical trial data, and potential precedent-setting budget liabilities as reasons for refusal.

For families of children with severe, intractable epilepsies who do not respond to Epidyolex, navigating the IFR pathway has proven heartbreakingly difficult, forcing many community fundraisers to cover thousands of pounds monthly for private whole-plant oils like Bedrolite or Celixir.

Because of NHS commissioning barriers, over 99.5% of all medical cannabis patients in the UK receive their care through private specialist clinics. Understanding the operational differences between these two pathways is essential for anyone seeking legal treatment:

Eligibility: The baseline clinical requirement is identical across both sectors: you must have a formally diagnosed qualifying health condition (e.g. chronic neuropathy, fibromyalgia, PTSD, treatment-resistant depression, Crohn's disease) and have attempted at least two conventional NHS treatments or therapies that proved ineffective or caused intolerable side effects.

Cost Structure: Private clinics charge consultation fees (£40–£200 for initial assessments, £30–£75 for mandatory quarterly reviews). Medication costs are paid entirely out of pocket by the patient, ranging from £5.00 to £12.00 per gram for dried flower and £30 to £180 per bottle for calibrated oral oils.

Access Schemes: To alleviate financial strain, several private clinics offer subsidized access registries (such as T21/Project Twenty21, the Curaleaf Access Scheme, and the Mamedica Access Scheme for veterans and low-income patients). These initiatives provide reduced consultation fees and capped medication costs in exchange for patient-reported real-world evidence data.

Under UK law, general practitioners (GPs) cannot write initial prescriptions for cannabis-based medicinal products; legislation requires initial prescriptions to be made by a doctor on the GMC Specialist Register.

However, your NHS GP plays an essential role in your journey. To register with any legal private cannabis clinic, you will need to provide your Summary Care Record (SCR) or an official medical summary letter detailing your diagnosis history, current prescriptions, and past treatments.

You do not need formal permission or a referral letter from your GP to contact a private clinic. By law under the Data Protection Act and UK GDPR, you have the right to request a full copy of your medical history from your GP surgery free of charge.

Maintaining open, transparent communication with your GP is vital. Private cannabis clinics send routine clinical update letters to your registered NHS GP after every consultation to ensure continuity of care and prevent adverse drug-drug interactions.